Literature DB >> 29455236

Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma.

Tomonori Nakazato1, Satoshi Takanashi2,3, Motoharu Hirano3, Chisako Ito2, Yuriko Fujita2, Yuki Osada2, Yoshinobu Aisa2, Takehiko Mori4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29455236     DOI： 10.1007/s00277-018-3279-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases.

Authors:  Kota Yoshifuji; Yoshihiro Umezawa; Ayako Ichikawa; Ken Watanabe; Osamu Miura; Masahide Yamamoto
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Production of insulin antibody associated with relapsed hodgkin's lymphoma.

Authors:  Masatoshi Ikeda; Masaki Fujimura; Kentaro Kurosawa; Shunsuke Tsugawa; Yui Sakuramachi; Kiyoko Takano; Shintaro Okamura; Masako Kitatani; Futoshi Iioka; Satoru Tsujii; Yasuaki Hayashino
Journal:  Diabetol Int       Date:  2021-10-16

3.  Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient.

Authors:  Keisuke Tanaka; Mai Kuboki; Satoshi Koi; Shigeo Toyota
Journal:  Intern Med       Date:  2019-11-22       Impact factor: 1.271

4.  Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series.

Authors:  Satoshi Ichikawa; Noriko Fukuhara; Kei Saito; Koichi Onodera; Tsuyoshi Shirai; Yasushi Onishi; Hisayuki Yokoyama; Hiroshi Fujii; Ryo Ichinohasama; Hideo Harigae
Journal:  Int J Hematol       Date:  2020-01-18       Impact factor: 2.319

5.  Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).

Authors:  Yasunobu Sekiguchi; Hiroko Iizuka; Haruko Takizawa; Keiji Sugimoto; Sakura Sakajiri; Tadaaki Inano; Yasutaka Fukuda; Syuichi Shirane; Yasuharu Hamano; Shigeki Tomita; Hiroshi Izumi; Mitsuo Okubo; Noriko Nakamura; Tomohiro Sawada; Naoya Sekiguchi; Masaaki Noguchi
Journal:  Intern Med       Date:  2020-05-26       Impact factor: 1.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.